The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.50 (2.86%)
Spread: 1.00 (5.714%)
Open: 17.50
High: 18.00
Low: 17.50
Prev. Close: 17.50
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of LeanBiome in Muscletech

15 Jan 2024 07:00

RNS Number : 5934Z
OptiBiotix Health PLC
15 January 2024
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of LeanBiome® in Muscletech®

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare announces the forthcoming launch of LeanBiome® in Muscletech®, one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company (see About Us · MuscleTech). The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK - see https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html 

 

Muscletech® is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world. LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and will be launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels.

 

LeanBiome® is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome® contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes (frontiersin.org)

 

 

Stephen OHara, CEO of OptiBiotix Health plc commented: "We are very pleased to announce the launch of LeanBiome® with such a well-known and internationally respected sports brand such as Muscletech®. LeanBiome® has been formulated to support anyone interested in improving their fitness for leisure or the elite athlete. It is supported by multiple published clinical studies which show it helps reduce body fat around the waist and hips, improving body leanness whilst enhancing the diversity of the gut microbiome to improve stamina and overall fitness.

 

"LeanBiome® is a unique product which is increasingly being recognised by major sports brands as a key differentiator from existing products and has the potential to have a major impact in the sports nutrition and health and fitness markets."

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

Duncan Vasey / Lucy Williams

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

About OptiBiotix www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBTMFTMTJBBBI
Date   Source Headline
26th Jul 202212:31 pmRNSResult of AGM
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich
1st Jul 20227:00 amRNSDirector Appointment and Director Dealing
28th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSProBiotix Health - Appointment of CEO
31st Mar 20227:01 amRNSAdmission of ProBiotix Health plc to AQSE
25th Mar 20222:36 pmRNSDirector/PDMR Shareholding
18th Mar 20222:00 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSIntention to list ProBiotix Health on AQSE
9th Mar 20227:00 amRNSExercise of warrants
1st Mar 20227:00 amRNSCommercial Appointments
28th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSCommercial and strategy update
1st Feb 20227:00 amRNSConsumer study of LPLDL in Cholbiome products
27th Jan 202210:38 amRNSExercise of Warrants
18th Jan 20227:00 amRNSPublication of third human study on LPLDL
7th Jan 20227:00 amRNSIssue of options
5th Jan 20227:00 amRNSOptiBiotix obtains BRC accreditation
15th Dec 20217:00 amRNSExclusive sales and distribution agreement
9th Dec 20217:00 amRNSLaunch of GoFigure range with Apollo Hospitals
1st Dec 202112:00 pmRNSInvestor presentation
1st Dec 20217:00 amRNSLaunch of LeanBiome with global nutrition leader
17th Nov 20217:00 amRNSFormation of OptiBiotix Health India
15th Nov 20214:59 pmRNSHolding(s) in Company
25th Oct 20217:00 amRNSSlimBiome® Approved by Health Canada
30th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSDirector dealing
31st Aug 20217:00 amRNSInvestor update
10th Aug 20217:00 amRNSExtension of territories for Seed Health’s DS-01
5th Aug 20217:00 amRNSTrading and commercial update
9th Jul 202110:49 amRNSResult of AGM
6th Jul 20217:00 amRNSFurther sales expansion in Asia
17th Jun 20217:00 amRNSFinal Results
19th May 20212:00 pmRNSSkinBioTherapeutics plc shareholding
21st Apr 20217:00 amRNSDirector/PDMR Shareholding
16th Apr 20217:00 amRNSDirector’s Dealing
23rd Mar 20217:00 amRNSDirectorate Changes
17th Mar 20217:00 amRNSCommercial strategy update
2nd Mar 20217:00 amRNSDirector Appointment
24th Feb 20217:00 amRNSInvestor update
18th Feb 20217:00 amRNSStrategy and commercial update
2nd Feb 20217:00 amRNSProposed Director appointment
19th Jan 20217:00 amRNSNew appointments
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.